Banner image © ACC/Nick Agro 2022
Day 1 (April 2) at ACC 2022 was a big day for PHRI researchers. At the first Late Breaking Clinical Trials session, PHRI Senior Scientist PJ Devereaux presented the findings of POISE-3 (tranexamic acid in patients undergoing noncardiac surgery), simultaneously published in The New England Journal of Medicine (NEJM).
Also on Day 1, PHRI Senior Scientist Shamir Mehta presented on the effects of complete revascularization on angina-related quality of life in patients with ST-segment elevation myocardial infarction, in a pre-specified analyis of the COMPLETE trial.
On Day 2, Mark Loeb presented findings on how flu vaccines protect heart failure patients, from the PHRI study, IVVE. Mark Loeb is Division Director, Infectious Diseases, at McMaster University.
PJ Devereaux and Maura Marcucci
Also on Day, 2, PHRI Scientist Sanjit Jolly presented findings from the SYNERGY stent registry, part of PHRI’s CLEAR SYNERGY (OASIS-9) trial.
On Day 3 at ACC 2022, PHRI Scientist Maura Marcucci presented on the effects of hypotension-avoidance vs hypertension-avoidance strategies in patients undergoing noncardiac surgery (a sub-study of the PHRI trial, POISE-3).
PHRI Research Fellow Harry Klimis presented abstract on RADICAL PC analysis: uncontrolled CV risk factors in men with prostate cancer at ACC22
Washington, DC – ACC22 – Speakers and attendees during the LBCT I Press Conference at the American College of Cardiology Scientific Session and Expo, here today Saturday, April 2, 2022, at the Walter E Washington Convention Center in Washington, DC. ACC22 features the latest practice-changing scientific breakthroughs in basic, translational, clinical and population science in cardiology with cardiovascular experts from around the world. Photo by © ACC/Nick Agro 2022.